Curis Inc (CRIS) (Q3 2026) Earnings Call Highlights: Strong PCNSL Response Rates and CLL ...
Curis Inc (CRIS) reported an 86% response rate in BTK-naive PCNSL patients and advancing CLL proof-of-concept data, while managing a $8.1 million quarterly net loss and relying on October financing Related Stocks: CRIS ,